Menezes Marcus Vinicius Martins de, Cestari Anna Letícia Oliveira, Almeida Orlando, Alvarenga Marcelo, Pinto Glauce Aparecida, Gurgel Maria Salete Costa, Souza Gustavo Antônio de, Zeferino Luiz Carlos
Centro de Atenção Integral à Saúde da Mulher, Universidade Estadual de Campinas, Rua Alexander Fleming 101, CEP 13083-970 Campinas, São Paulo, Brazil.
Sao Paulo Med J. 2006 May 4;124(3):121-4. doi: 10.1590/s1516-31802006000300002.
Breast cancer is thought to derive from progressively aberrant, non-invasive breast lesions, but it is not known exactly how invasive breast cancer develops from these lesions. The aim of this study was to verify the changes in c-erbB-2 and p53 protein expression between non-neoplastic ducts, ductal carcinoma in situ and invasive ductal carcinoma found in the same breast.
This was a cross-sectional study at Centro de Atenção Integral à Saúde da Mulher, Campinas, Brazil.
Fifty-six women with invasive ductal carcinoma and ductal carcinoma in situ in the same breast were included. The expression of c-erbB-2 and p53 proteins was assessed in non-neoplastic and neoplastic cells using immunohistochemical techniques.
The c-erbB-2 protein was absent in non-neoplastic ducts but was present in 46% and 36% of in situ and invasive carcinoma components, respectively. Only 2% of non-neoplastic ducts, and 18% and 16% of ductal carcinoma in situ and invasive carcinoma components, respectively, were positive for p53 protein. No significant difference in c-erbB-2 and p53 protein expression was observed between in situ and invasive components. The nuclear grade agreement between in situ and invasive carcinoma was very good.
The invasiveness of ductal carcinoma in situ seems to be independent of the Her-2/neu and TP53 genes. The general features of an occurrence of breast carcinoma are formulated at the outset of carcinogenesis, and the Her-2/neu and TP53 genes are involved.
乳腺癌被认为起源于逐渐异常的非侵袭性乳腺病变，但尚不清楚侵袭性乳腺癌是如何从这些病变发展而来的。本研究的目的是验证同一乳腺中正常导管、导管原位癌和浸润性导管癌之间c-erbB-2和p53蛋白表达的变化。
这是一项在巴西坎皮纳斯妇女综合健康中心开展的横断面研究。
纳入56例同一乳腺患有浸润性导管癌和导管原位癌的女性。采用免疫组织化学技术评估正常和肿瘤细胞中c-erbB-2和p53蛋白的表达。
正常导管中不存在c-erbB-2蛋白，但分别有46%和36%的原位癌和浸润癌成分中存在该蛋白。只有2%的正常导管以及分别有18%和16%的导管原位癌和浸润癌成分p53蛋白呈阳性。原位癌和浸润癌成分之间c-erbB-2和p53蛋白表达未观察到显著差异。原位癌和浸润癌之间的核分级一致性非常好。
导管原位癌的侵袭性似乎独立于Her-2/neu和TP53基因。乳腺癌发生的一般特征在致癌过程开始时就已形成，且Her-2/neu和TP53基因参与其中。
